Taysha Gene Therapies Announces 2024 Annual Meeting of Stockholders

TL;DR

<b>Taysha Gene Therapies will hold its virtual Annual Meeting on May 29, 2024, to elect directors and ratify auditors.</b>

AI Summary

Taysha Gene Therapies, Inc. (TSHA) filed a Proxy Statement (DEF 14A) with the SEC on April 18, 2024. Annual Meeting scheduled for May 29, 2024, at 3:00 p.m. ET, held virtually. Key agenda items include election of two Board of Directors nominees: Sean Stalfort and Alison Long, M.D., Ph.D. Stockholders will vote on ratifying Deloitte & Touche LLP as the independent auditor for the fiscal year ending December 31, 2024. Record date for stockholders eligible to vote is April 4, 2024. Stockholders can submit questions in advance via www.proxyvote.com until May 27, 2024.

Why It Matters

For investors and stakeholders tracking Taysha Gene Therapies, Inc., this filing contains several important signals. The election of directors and ratification of auditors are standard corporate governance procedures crucial for company oversight and financial integrity. The virtual format allows for broader stockholder participation and accessibility, while advance question submission ensures relevant topics are addressed.

Risk Assessment

Risk Level: low — Taysha Gene Therapies, Inc. shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting and does not contain new financial or operational information that would indicate significant risk.

Analyst Insight

Stockholders should review the nominees and auditor ratification to make informed voting decisions at the upcoming annual meeting.

Key Numbers

• May 29, 2024 — Annual Meeting Date (Date of the Annual Meeting of Stockholders)
• April 4, 2024 — Record Date (Stockholders of record on this date are eligible to vote)
• May 27, 2024 — Question Submission Deadline (Deadline to submit questions in advance of the meeting)
• 2027 — Director Term End (Term for elected directors will extend until the 2027 Annual Meeting)

Key Players & Entities

• Taysha Gene Therapies, Inc. (company) — Registrant
• Sean Stalfort (person) — Nominee for Board of Directors
• Alison Long, M.D., Ph.D. (person) — Nominee for Board of Directors
• Deloitte & Touche LLP (company) — Independent registered public accounting firm

FAQ

Industry Context

Taysha Gene Therapies is a clinical-stage biotechnology company focused on developing novel gene therapies for monogenic severe neurological rare diseases.

Regulatory Implications

The filing is a standard proxy statement under Section 14(a) of the Securities Exchange Act of 1934, requiring disclosure of information for stockholder voting.

What Investors Should Do

1. Review the backgrounds and qualifications of director nominees Sean Stalfort and Alison Long, M.D., Ph.D.
2. Evaluate the proposal to ratify Deloitte & Touche LLP as the independent auditor for fiscal year 2024.
3. Ensure voting rights are exercised by the record date of April 4, 2024, by participating in the virtual meeting or submitting a proxy.

Key Dates

• 2024-05-29: Annual Meeting of Stockholders — To elect directors and ratify auditors.
• 2024-04-04: Record Date — Determines eligibility to vote at the Annual Meeting.
• 2024-05-27: Advance Question Submission Deadline — Last day for stockholders to submit questions for the meeting.

Year-Over-Year Comparison

This filing is a Definitive Proxy Statement (DEF 14A) for the 2024 Annual Meeting, providing details on upcoming votes and board nominations.

Filing Documents

• d773782ddef14a.htm (DEF 14A) — 360KB
• g773782dsp1.jpg (GRAPHIC) — 3KB
• g773782dsp1a.jpg (GRAPHIC) — 4KB
• g773782dsp1b3.jpg (GRAPHIC) — 1KB
• g773782g02a01.jpg (GRAPHIC) — 37KB
• 0001193125-24-100792.txt (&nbsp;) — 423KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 24

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 27 Summary Compensation Table 27 Outstanding Equity Awards as of December 31, 2023 29 DIRECTOR COMPENSATION 33 SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS 36 TRANSACTIONS WITH RELATED PERSONS AND INDEMNIFICATION 37 Related Person Transactions Policy and Procedures 37 Certain Related Person Transactions 37 HOUSEHOLDING OF PROXY MATERIALS 40 OTHER MATTERS 41 i Table of Contents TAYSHA GENE THERAPIES, INC. 3000 Pegasus Park Drive Suite 1430 Dallas, Texas 75247 PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS May 29, 2024 QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING Why did I receive a notice regarding the availability of proxy materials on the internet? Pursuant to rules adopted by the Securities and Exchange Commission (the SEC), we have elected to provide access to our proxy materials over the internet. Accordingly, we have sent you a Notice of Internet Availability of Proxy Materials (the Notice) because our Board of Directors is soliciting your proxy to vote at the 2024 Annual Meeting of Stockholders, including at any adjournments or postponements of the meeting. All stockholders will have the ability to access the proxy materials on the website referred to in the Notice or request to receive a printed set of the proxy materials. Instructions on how to access the proxy materials over the internet or to request a printed copy may be found in the Notice. We intend to mail the Notice on or about April 18, 2024, to all stockholders of record entitled to vote at the Annual Meeting. How do I attend the Annual Meeting? The Annual Meeting will be a virtual stockholder meeting held on Wednesday, May 29, 2024, at 3:00 p.m., Eastern Time, through which you can listen to the meeting and vote online. The Annual Meeting can be accessed by visiting www.virtualshareholdermeeting.com/TSHA2024 and entering the control number included in your N

View Full Filing

View this DEF 14A filing on SEC EDGAR